Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.55 |
| ▸ | CTSK | P43235 | 6/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30968591 | 1.00 | CTSS (0.55) | CTSSCTSKPTPN1SCN9AKMT2A | |
| SCHEMBL30968605 | 1.00 | CTSS (0.55) | CTSSCTSKPTPN1SCN9AKMT2A | |
| SCHEMBL30968603 | 0.88 | CTSS (0.57) | CTSSCTSKPTPN1SCN9AKMT2A | |
| SCHEMBL30968604 | 0.88 | CTSS (0.57) | CTSSCTSKPTPN1SCN9AKMT2A | |
| SCHEMBL29253672 | 0.88 | CTSS (0.57) | CTSSCTSKPTPN1SCN9AKMT2A | |
| SCHEMBL30968648 | 0.83 | ATM (0.53) | CTSSCTSKKMT2AATMCTSL | |
| SCHEMBL30968615 | 0.83 | ATM (0.53) | CTSSCTSKKMT2AATMCTSL | |
| SCHEMBL30968600 | 0.83 | ATM (0.53) | CTSSCTSKKMT2AATMCTSL | |
| SCHEMBL30968593 | 0.75 | CARM1 (0.48) | — | |
| SCHEMBL30968590 | 0.75 | CARM1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118302410-A | Deuterated functionalized derivatives of alpha-alanine, in particular for the treatment of neurological diseases | 雅盖隆大学 | 2024-07-05 | — | — | CN | disclosed |